Ahmad A Tarhini1, Sandra J Lee2,3, F Stephen Hodi3, Uma N M Rao4, Gary I Cohen5, Omid Hamid6, Laura F Hutchins7, Jeffrey A Sosman8, Harriett M Kluger9, Zeynep Eroglu1, Henry B Koon10, Donald P Lawrence11, Kari L Kendra12, David R Minor13, Carrie B Lee14, Mark R Albertini15, Lawrence E Flaherty16, Teresa M Petrella17, Howard Streicher18, Vernon K Sondak1, John M Kirkwood4. 1. H. Lee Moffitt Comprehensive Cancer Center, Tampa, FL. 2. Harvard Medical School, Boston, MA. 3. Dana-Farber Cancer Institute, Boston, MA. 4. University of Pittsburgh Medical Center, Pittsburgh, PA. 5. Greater Baltimore Medical Center, Baltimore, MD. 6. Angeles Clinic & Research Institute, Santa Monica, CA. 7. University of Arkansas, Little Rock, AR. 8. Northwestern University Feinberg School of Medicine, Chicago, IL. 9. Yale University, New Haven, CT. 10. Case Western Reserve University, Cleveland, OH. 11. Massachusetts General Hospital, Boston, MA. 12. Ohio State University, Columbus, OH. 13. Sutter-California Pacific Medical Center, San Francisco, CA. 14. University of North Carolina at Chapel Hill, Chapel Hill, NC. 15. University of Wisconsin, Madison, WI. 16. Wayne State University/Karmanos Cancer Institute, Detroit, MI. 17. Odette Cancer Center, Toronto, Ontario, Canada. 18. National Cancer Institute, Rockville, MD.
Abstract
PURPOSE: Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10). E1609 evaluated the safety and efficacy of ipilimumab at 3 mg/kg (ipi3) and ipi10 versus HDI. PATIENTS AND METHODS: E1609 was a phase III trial in patients with resected cutaneous melanoma (American Joint Committee on Cancer 7th edition stage IIIB, IIIC, M1a, or M1b). It had 2 coprimary end points: OS and RFS. A 2-step hierarchic approach first evaluated ipi3 versus HDI followed by ipi10 versus HDI. RESULTS: Between May 2011 and August 2014, 1,670 adult patients were centrally randomly assigned (1:1:1) to ipi3 (n = 523), HDI (n = 636), or ipi10 (n = 511). Treatment-related adverse events grade ≥ 3 occurred in 37% of patients receiving ipi3, 79% receiving HDI, and 58% receiving ipi10, with adverse events leading to treatment discontinuation in 35%, 20%, and 54%, respectively. Comparison of ipi3 versus HDI used an intent-to-treat analysis of concurrently randomly assigned patient cases (n = 1,051) and showed significant OS difference in favor of ipi3 (hazard ratio [HR], 0.78; 95.6% repeated CI, 0.61 to 0.99; P = .044; RFS: HR, 0.85; 99.4% CI, 0.66 to 1.09; P = .065). In the second step, for ipi10 versus HDI (n = 989), trends in favor of ipi10 did not achieve statistical significance. Salvage patterns after melanoma relapse showed significantly higher rates of ipilimumab and ipilimumab/anti-programmed death 1 use in the HDI arm versus ipi3 and ipi10 (P ≤ .001). CONCLUSION: Adjuvant therapy with ipi3 benefits survival versus HDI; for the first time to our knowledge in melanoma adjuvant therapy, E1609 has demonstrated a significant improvement in OS against an active control regimen. The currently approved adjuvant ipilimumab dose (ipi10) was more toxic and not superior in efficacy to HDI.
PURPOSE: Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10). E1609 evaluated the safety and efficacy of ipilimumab at 3 mg/kg (ipi3) and ipi10 versus HDI. PATIENTS AND METHODS: E1609 was a phase III trial in patients with resected cutaneous melanoma (American Joint Committee on Cancer 7th edition stage IIIB, IIIC, M1a, or M1b). It had 2 coprimary end points: OS and RFS. A 2-step hierarchic approach first evaluated ipi3 versus HDI followed by ipi10 versus HDI. RESULTS: Between May 2011 and August 2014, 1,670 adult patients were centrally randomly assigned (1:1:1) to ipi3 (n = 523), HDI (n = 636), or ipi10 (n = 511). Treatment-related adverse events grade ≥ 3 occurred in 37% of patients receiving ipi3, 79% receiving HDI, and 58% receiving ipi10, with adverse events leading to treatment discontinuation in 35%, 20%, and 54%, respectively. Comparison of ipi3 versus HDI used an intent-to-treat analysis of concurrently randomly assigned patient cases (n = 1,051) and showed significant OS difference in favor of ipi3 (hazard ratio [HR], 0.78; 95.6% repeated CI, 0.61 to 0.99; P = .044; RFS: HR, 0.85; 99.4% CI, 0.66 to 1.09; P = .065). In the second step, for ipi10 versus HDI (n = 989), trends in favor of ipi10 did not achieve statistical significance. Salvage patterns after melanoma relapse showed significantly higher rates of ipilimumab and ipilimumab/anti-programmed death 1 use in the HDI arm versus ipi3 and ipi10 (P ≤ .001). CONCLUSION: Adjuvant therapy with ipi3 benefits survival versus HDI; for the first time to our knowledge in melanoma adjuvant therapy, E1609 has demonstrated a significant improvement in OS against an active control regimen. The currently approved adjuvant ipilimumab dose (ipi10) was more toxic and not superior in efficacy to HDI.
Authors: Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria Atkinson; Stéphane Dalle; Andrew Haydon; Mikhail Lichinitser; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Michele Maio; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul Lorigan; Nageatte Ibrahim; Sandrine Marreaud; Alexander C J van Akkooi; Stefan Suciu; Caroline Robert Journal: N Engl J Med Date: 2018-04-15 Impact factor: 91.245
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: David H Lawson; Sandra Lee; Fengmin Zhao; Ahmad A Tarhini; Kim A Margolin; Marc S Ernstoff; Michael B Atkins; Gary I Cohen; Theresa L Whiteside; Lisa H Butterfield; John M Kirkwood Journal: J Clin Oncol Date: 2015-09-08 Impact factor: 44.544
Authors: J M Kirkwood; J G Ibrahim; V K Sondak; J Richards; L E Flaherty; M S Ernstoff; T J Smith; U Rao; M Steele; R H Blum Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: J M Kirkwood; J G Ibrahim; J A Sosman; V K Sondak; S S Agarwala; M S Ernstoff; U Rao Journal: J Clin Oncol Date: 2001-05-01 Impact factor: 44.544
Authors: Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé Journal: Lancet Oncol Date: 2009-12-08 Impact factor: 41.316
Authors: Ahmad Tarhini; Sameer R Ghate; Raluca Ionescu-Ittu; Ameur M Manceur; Briana Ndife; Philippe Jacques; François Laliberté; Antonio Nakasato; Rebecca Burne; Mei Sheng Duh Journal: Melanoma Res Date: 2018-12 Impact factor: 3.599
Authors: Tomohide Tatsumi; Lisa S Kierstead; Elena Ranieri; Loreto Gesualdo; Francesco P Schena; James H Finke; Ronald M Bukowski; Jan Mueller-Berghaus; John M Kirkwood; William W Kwok; Walter J Storkus Journal: J Exp Med Date: 2002-09-02 Impact factor: 14.307
Authors: Dale Han; Alexander C J van Akkooi; Richard J Straker; Adrienne B Shannon; Giorgos C Karakousis; Lin Wang; Kevin B Kim; Douglas Reintgen Journal: Clin Exp Metastasis Date: 2021-05-07 Impact factor: 4.510
Authors: Ahmad A Tarhini; Ni Kang; Sandra J Lee; F Stephen Hodi; Gary I Cohen; Omid Hamid; Laura F Hutchins; Jeffrey A Sosman; Harriet M Kluger; Zeynep Eroglu; Henry B Koon; Donald P Lawrence; Kari L Kendra; David R Minor; Carrie B Lee; Mark R Albertini; Lawrence E Flaherty; Teresa M Petrella; Howard Streicher; Vernon K Sondak; John M Kirkwood Journal: J Immunother Cancer Date: 2021-05 Impact factor: 13.751
Authors: Ahmad A Tarhini; Sandra J Lee; F Stephen Hodi; Uma N M Rao; Gary I Cohen; Omid Hamid; Laura F Hutchins; Jeffrey A Sosman; Harriett M Kluger; Zeynep Eroglu; Henry B Koon; Donald P Lawrence; Kari L Kendra; David R Minor; Carrie B Lee; Mark R Albertini; Lawrence E Flaherty; Teresa M Petrella; Howard Streicher; Vernon K Sondak; John M Kirkwood Journal: J Clin Oncol Date: 2019-12-27 Impact factor: 50.717